Pirfenidone, a drug that inhibits TGF-β1 signaling, has recently been approved for treating pulmonary fibrosis (94) and our results suggest this compound may have potential to promote bacterial clearance during TB treatment. The gene discussed is TGFB1; the disease is pulmonary fibrosis.